Hormel Foods through its incubator arm 199 Ventures has partnered with The Better Meat Co. to develop a process of making mycoprotein out of a potato-based fermentation.
The partnership would be tapping Better Meat’s technology in developing the process of creating the mycoprotein trade-named Rhiza.
Better Meat's process involves feeding potatoes to fungi, which in turn convert them into a “pale-colored, neutral-tasting ingredient” similar to chicken meat.
Founded in 1891, Minnesota-based Hormel has primarily been a meat company throughout much of its history, responsible for such meat products as Spam and Hormel Corned Beef.
But in recent years, Hormel has been shifting away from its “meat-centric reputation.”
Hormel CEO Jim Snee said in February that he soon expects at least 25 percent of their sales to come from non-meat products.
According to Fred Halvin, vice president of corporate development at Hormel Foods, with food culture changing rapidly, they would want to address the people's curiosity and willingness to try great tasting, plant-based proteins.
Halvin added that as a global branded food company, Hormel would want to offer delicious and convenient mycoprotein and plant-based protein products.
A Hormel spokesman said the company acknowledges that the alternative protein market has “a high growth trajectory.” He added Hormel Foods want to make sure that it to grow their product offerings in those categories.


Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Instagram Outage Disrupts Thousands of U.S. Users
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Australia’s December Trade Surplus Expands but Falls Short of Expectations
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions
Oil Prices Slide on US-Iran Talks, Dollar Strength and Profit-Taking Pressure
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 



